Dr. Robert Nagourney is an internationally recognized pioneer in cancer research and personalized cancer treatment.
With more than 20 years experience in human tumor primary culture analyses, Dr. Nagourney has authored more than 100 manuscripts, book chapters and abstracts including publications in the Journal of Clinical Oncology, Gynecologic Oncology and the Journal of the National Cancer Institute.
Over the past 20+ years, Dr. Nagourney and his team here at the Nagourney Cancer Institute have developed a laboratory technique, functional profiling, that measures how cancer cells respond when they are exposed to a wide variety of drugs and drug combinations.
Why is this important?
By using this approach, we try to determine in the laboratory the best drugs for each patient before they receive them. This reduces the guesswork in selecting the right drug treatment for you and is why our analysis is more powerful than genomic testing offered by most centers.
This helps us select the most effective and least toxic drug regimen for your particular cancer.
To understand better how (and why) this approach works, click here to view a newly uploaded 4 minute video collage of TV segments filmed over the years about our work. Further down on this page is also a link to Dr. Nagourney's TEDx talk.
Every cancer is unique. Call us at 800-542-4357 to find out how we can help you in your particular situation. You can also contact us via email here.
Medical professionals please click here for more technical information and test requirements.
Among his many research accomplishments, Dr. Nagourney is recognized for his work in the introduction of Cisplatin/Gemcitabine doublets (two drugs given together) in the treatment of advanced ovarian and breast cancers.
Want to know more about cancer, cancer research and how best to treat cancer?
Click the link below to watch Dr. Nagourney share his unique insight into these topics and explain his treatment philosophy in this engaging TEDx Talk.
You can also click here to see additional videos and TV appearances by Dr. Nagourney on our Cancer Resource Center page.
Most centers offer genomics testing. But only a minority of patients have genetic changes that can be used for therapy.
Only functional analyses can capture each patient's tumor in real time and provide insights that can improve drug selection and treatment decisions.
How do we do this?
To find the most effective treatment for you, living tumor cells are collected during biopsy or surgery. It's important to call us BEFORE your biopsy or surgery so we can arrange the collection.
Or we can test fluid accumulations from the lung (pleural effusion) or abdomen (ascites) if they contain enough cancer cells. Also, if you have leukemia, lymphoma, or myeloma, we can often use a blood or bone marrow specimen.
We then expose your living cancer cells in the laboratory to chemotherapy drugs, targeted agents and various drug combinations.
How does this help you?
This eliminates much of the "guess work" prior to your undergoing the potentially toxic side effects of drug regimens that could prove to be of little value against your cancer.
By using combinations of drugs found most effective against a patient's cancer cells in the laboratory, Dr. Nagourney and his team have been able to double response rates and improve survival for his patients.
We can test most types of cancers, solid and hematologic (blood).
Samples are sent to us from all over the US and internationally. Since the test involves living cancer cells, the samples MUST arrive in a very timely manner, within 24-36 hours.
Results are generally available within 7 days of receipt of your cancer sample in our laboratory.
For more information on how to get your cancer sample sent to us for analysis call us at 800-542-4357 or click here to contact us via email.
No matter if you are newly diagnosed or have advanced cancer, contact us, we are here to help.
Mantle zone lymphoma represents approximately 6% of all non-Hodgkin lymphomas diagnosed in the US each year.
It is named for the region in the lymph...
March is colorectal cancer awareness month.
Colorectal cancer is the third most common cancer for both men and women in the US with 101,420 new colon...
A recent editorial entitled "More Proof That Less Chemo is Best in Elderly Colorectal Cancer Patients" (David Kerr, Medscape, January 24, 2019)...